Prosecution Insights
Last updated: August 15, 2026

STEMCELL Technologies Canada Inc.

12 pending office actions • 7 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

12
Total Pending OAs
7
Non-Final OAs
4
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

6
Hard (50%)
4
Medium (33%)
2
Easy (17%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (8%)
§102 only1 (8%)
§112 only2 (17%)
Double-patenting + other3 (25%)
Multi-statute (no §101)5 (42%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

9
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
3
Business / Other
25% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

120 h
Manual time on pending OAs
24 h
Time saved (low, 20%)
42 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BEHARRY, ZANNA MARIA 1 23.2% +52.7%
CANDELARIA, JULIANA IRENE 1 0.0% +0.0%
TAKENAKA, RISA 1 28.6% +100.0%
KNIGHT, TERESA E 1 65.7% +48.7%
PAULUS, ERIN VIRGINIA 1 25.0% +92.3%
VAN BUREN, LAUREN K 1 39.5% +58.0%
CHEN, STACY BROWN 1 66.0% +40.4%
LEITH, NANCY J 1 74.7% +43.8%
MONTANARI, DAVID A 1 64.8% +49.2%
VIVLEMORE, TRACY ANN 1 73.0% +6.7%

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18038088 DENSITY-ADJUSTED LIQUIDS AND METHODS USING SAME VAN BUREN, LAUREN K 66d overdue
18559925 METHODS FOR DELIVERING GENOME EDITING MOLECULES TO THE NUCLEUS OR CYTOSOL OF A CELL AND USES THEREOF KNIGHT, TERESA E 84d
18726305 MODIFIED HEMATOPOIETIC STEM CELLS AND USES THEREOF BEHARRY, ZANNA MARIA
18718866 COMPOSITIONS AND METHODS FOR EXPANDING KERATINOCYTES CANDELARIA, JULIANA IRENE
18709331 METHODS TO GENERATE ENHANCED TUMOR INFILTRATING LYMPHOCYTES THROUGH MICROFLUIDIC DELIVERY TAKENAKA, RISA
18553292 REPROGRAMMING OF CELLS AND USES THEREOF PAULUS, ERIN VIRGINIA
17425709 ANUCLEATE CELL-DERIVED VACCINES RIGA, MICHAEL ANGELO

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18038088 DENSITY-ADJUSTED LIQUIDS AND METHODS USING SAME VAN BUREN, LAUREN K 66d overdue
18318842 DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSE CHEN, STACY BROWN 1d overdue
18559925 METHODS FOR DELIVERING GENOME EDITING MOLECULES TO THE NUCLEUS OR CYTOSOL OF A CELL AND USES THEREOF KNIGHT, TERESA E 84d
18726305 MODIFIED HEMATOPOIETIC STEM CELLS AND USES THEREOF BEHARRY, ZANNA MARIA
18709331 METHODS TO GENERATE ENHANCED TUMOR INFILTRATING LYMPHOCYTES THROUGH MICROFLUIDIC DELIVERY TAKENAKA, RISA
18553292 REPROGRAMMING OF CELLS AND USES THEREOF PAULUS, ERIN VIRGINIA
18190335 INTRACELLULAR DELIVERY OF BIOMOLECULES TO CELLS COMPRISING A CELL WALL LEITH, NANCY J
18017512 SYSTEMS AND METHODS FOR DIFFERENTIATING HEMATOPOIETIC CELLS MONTANARI, DAVID A

Top Art Units

Art UnitApps
1634 2
1638 2
1631 1
1672 1
1636 1
1632 1
1644 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18726305 MODIFIED HEMATOPOIETIC STEM CELLS AND USES THEREOF BEHARRY, ZANNA MARIA §102§103§112DP Non-Final OA Pending Jul 02, 2024
18718866 COMPOSITIONS AND METHODS FOR EXPANDING KERATINOCYTES CANDELARIA, JULIANA IRENE §103§112 Non-Final OA Pending Jun 12, 2024
18709331 METHODS TO GENERATE ENHANCED TUMOR INFILTRATING LYMPHOCYTES THROUGH MICROFLUIDIC DELIVERY TAKENAKA, RISA §102§112 Non-Final OA Pending May 10, 2024
18559925 METHODS FOR DELIVERING GENOME EDITING MOLECULES TO THE NUCLEUS OR CYTOSOL OF A CELL AND USES THEREOF KNIGHT, TERESA E 1634 §102§112 Non-Final OA 84d Pending Nov 09, 2023
18553292 REPROGRAMMING OF CELLS AND USES THEREOF PAULUS, ERIN VIRGINIA 1631 §101§102§103§112 Final Rejection Pending Sep 29, 2023
18038088 DENSITY-ADJUSTED LIQUIDS AND METHODS USING SAME VAN BUREN, LAUREN K 1638 §102§103§112 Non-Final OA 66d overdue Pending May 22, 2023
18318842 DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSE CHEN, STACY BROWN 1672 §112 Final Rejection 1d overdue Pending May 17, 2023
18190335 INTRACELLULAR DELIVERY OF BIOMOLECULES TO CELLS COMPRISING A CELL WALL LEITH, NANCY J 1636 §112DP Non-Final OA Pending Mar 27, 2023
18017512 SYSTEMS AND METHODS FOR DIFFERENTIATING HEMATOPOIETIC CELLS MONTANARI, DAVID A 1632 §102 Final Rejection Pending Jan 23, 2023
17822942 INTRACELLULAR DELIVERY OF COMPLEXES VIVLEMORE, TRACY ANN 1638 §112 Non-Final OA Pending Aug 29, 2022
17425709 ANUCLEATE CELL-DERIVED VACCINES RIGA, MICHAEL ANGELO 1634 §102§103§112Other Non-Final OA Pending Jul 23, 2021
17282709 INTRACELLULAR DELIVERY OF BIOMOLECULES TO ENHANCE ANTIGEN PRESENTING CELL FUNCTION JUEDES, AMY E 1644 §103§112DP Final Rejection Pending Apr 02, 2021

Managing STEMCELL Technologies Canada Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month